Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the follow
Tweet Content
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria:
OP0195
LBA0005
POS0803
OP0138
https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
Links
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? | RheumNow
https://buff.ly/4c1xDu2
Show on Archive Page
On
Display in Search Results
On
PDQ
Off